JP2011079859A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011079859A5 JP2011079859A5 JP2010276634A JP2010276634A JP2011079859A5 JP 2011079859 A5 JP2011079859 A5 JP 2011079859A5 JP 2010276634 A JP2010276634 A JP 2010276634A JP 2010276634 A JP2010276634 A JP 2010276634A JP 2011079859 A5 JP2011079859 A5 JP 2011079859A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oral administration
- release pharmaceutical
- administration according
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 238000013270 controlled release Methods 0.000 claims 17
- 238000002360 preparation method Methods 0.000 claims 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 10
- -1 2-Aminothiazol-4-yl Chemical group 0.000 claims 8
- 239000000654 additive Substances 0.000 claims 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000000017 hydrogel Substances 0.000 claims 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 5
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 230000003078 antioxidant effect Effects 0.000 claims 4
- 235000006708 antioxidants Nutrition 0.000 claims 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 230000000996 additive effect Effects 0.000 claims 3
- 238000010828 elution Methods 0.000 claims 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 claims 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 229940000635 beta-alanine Drugs 0.000 claims 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000004359 castor oil Substances 0.000 claims 2
- 235000019438 castor oil Nutrition 0.000 claims 2
- 238000013329 compounding Methods 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 229960005337 lysine hydrochloride Drugs 0.000 claims 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 2
- 229960003194 meglumine Drugs 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- 239000002861 polymer material Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 2
- 229960002920 sorbitol Drugs 0.000 claims 2
- 229960004793 sucrose Drugs 0.000 claims 2
- 239000011975 tartaric acid Substances 0.000 claims 2
- 235000002906 tartaric acid Nutrition 0.000 claims 2
- 239000000811 xylitol Substances 0.000 claims 2
- 235000010447 xylitol Nutrition 0.000 claims 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 2
- 229960002675 xylitol Drugs 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 1
- 235000010378 sodium ascorbate Nutrition 0.000 claims 1
- 229960005055 sodium ascorbate Drugs 0.000 claims 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10133808P | 2008-09-30 | 2008-09-30 | |
| US61/101,338 | 2008-09-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531838A Division JP4688089B2 (ja) | 2008-09-30 | 2009-09-28 | 放出制御医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011079859A JP2011079859A (ja) | 2011-04-21 |
| JP2011079859A5 true JP2011079859A5 (enExample) | 2013-10-31 |
| JP5625855B2 JP5625855B2 (ja) | 2014-11-19 |
Family
ID=42073454
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531838A Active JP4688089B2 (ja) | 2008-09-30 | 2009-09-28 | 放出制御医薬組成物 |
| JP2010276634A Active JP5625855B2 (ja) | 2008-09-30 | 2010-12-13 | 放出制御医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531838A Active JP4688089B2 (ja) | 2008-09-30 | 2009-09-28 | 放出制御医薬組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20160184275A2 (enExample) |
| EP (2) | EP3827826A1 (enExample) |
| JP (2) | JP4688089B2 (enExample) |
| KR (1) | KR101524164B1 (enExample) |
| CN (2) | CN105232448A (enExample) |
| AU (1) | AU2009300752C1 (enExample) |
| BR (1) | BRPI0919466B1 (enExample) |
| CA (1) | CA2740342C (enExample) |
| CY (1) | CY1123724T1 (enExample) |
| DK (1) | DK2345410T3 (enExample) |
| ES (1) | ES2847876T3 (enExample) |
| HK (1) | HK1216232A1 (enExample) |
| HR (1) | HRP20210179T1 (enExample) |
| HU (1) | HUE052874T2 (enExample) |
| IL (1) | IL212033A (enExample) |
| LT (1) | LT2345410T (enExample) |
| MX (1) | MX351855B (enExample) |
| PL (1) | PL2345410T3 (enExample) |
| PT (1) | PT2345410T (enExample) |
| RU (1) | RU2495666C2 (enExample) |
| SI (1) | SI2345410T1 (enExample) |
| TW (1) | TWI478712B (enExample) |
| WO (1) | WO2010038690A1 (enExample) |
| ZA (1) | ZA201102406B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2144077C (en) * | 1992-09-18 | 2005-05-24 | Kazuhiro Sako | Hydrogel-type sustained-release preparation |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| US8877214B2 (en) | 2010-03-29 | 2014-11-04 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
| US20120070465A1 (en) * | 2010-03-29 | 2012-03-22 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
| JP6272695B2 (ja) | 2010-09-01 | 2018-01-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| JP6093762B2 (ja) * | 2011-10-21 | 2017-03-08 | 武田薬品工業株式会社 | 徐放性製剤 |
| WO2013147135A1 (ja) * | 2012-03-30 | 2013-10-03 | アステラス製薬株式会社 | 放出制御医薬組成物 |
| US20150031734A1 (en) | 2012-03-30 | 2015-01-29 | Astellas Pharma Inc. | Pharmaceutical composition containing mirabegron |
| EP2891493A4 (en) * | 2012-08-31 | 2016-05-18 | Astellas Pharma Inc | MEDICAL COMPOSITION ADMINISTERED ORALLY |
| JP2017078023A (ja) * | 2014-02-28 | 2017-04-27 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| CN104523635B (zh) * | 2014-12-23 | 2017-05-03 | 深圳万乐药业有限公司 | 米拉贝隆缓释药物组合物 |
| JP2018090490A (ja) | 2015-03-31 | 2018-06-14 | アステラス製薬株式会社 | ミラベグロン含有医薬組成物 |
| JP6618736B2 (ja) * | 2015-09-01 | 2019-12-11 | 沢井製薬株式会社 | ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法 |
| WO2017186593A1 (en) | 2016-04-25 | 2017-11-02 | Synthon B.V. | Tablets comprising mirabegron and solifenacin |
| EP3448366A1 (en) * | 2016-04-25 | 2019-03-06 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| PT3360866T (pt) | 2017-02-14 | 2019-02-19 | Tiefenbacher Alfred E Gmbh & Co Kg | Pró-fármacos de mirabegrom |
| KR102051132B1 (ko) * | 2017-03-17 | 2019-12-02 | 주식회사 종근당 | 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물 |
| KR20170088783A (ko) * | 2017-07-07 | 2017-08-02 | 지엘팜텍주식회사 | 미라베그론의 습식과립 조성물 |
| KR101937713B1 (ko) * | 2017-07-14 | 2019-01-14 | 주식회사 대웅제약 | 약제학적 제제 및 그 제조방법 |
| WO2019013583A2 (ko) | 2017-07-14 | 2019-01-17 | 주식회사 대웅제약 | 약제학적 제제 및 그 제조방법 |
| EP3292864A1 (en) | 2017-10-12 | 2018-03-14 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| US10478399B2 (en) * | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| EP3694492A1 (en) | 2017-10-12 | 2020-08-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| KR20190089758A (ko) | 2018-01-22 | 2019-07-31 | (주)동구바이오제약 | 미라베그론 또는 이의 약제학적으로 허용가능한 염을 함유하는 지속 방출 제제 |
| KR102371567B1 (ko) | 2018-04-06 | 2022-03-07 | 한미약품 주식회사 | 미라베그론이 함유된 방출 제어 약학적 조성물 |
| KR102659760B1 (ko) | 2018-10-18 | 2024-04-23 | 한미약품 주식회사 | 미라베그론이 함유된 방출 제어 약제학적 조성물 |
| KR102062791B1 (ko) | 2019-02-26 | 2020-01-06 | 신일제약 주식회사 | 미라베그론 또는 그의 약제학적으로 허용되는 염을 함유한 방출조절 제제 |
| JP7377782B2 (ja) * | 2019-09-04 | 2023-11-10 | 信越化学工業株式会社 | フィルム成形用組成物及びフィルム |
| AR121207A1 (es) * | 2020-01-31 | 2022-04-27 | Nippon Shinyaku Co Ltd | Composición de liberación controlada |
| KR102546923B1 (ko) | 2020-03-03 | 2023-06-26 | 동광제약 주식회사 | 미라베그론을 포함하는 제어 방출 제제 |
| CN113662922A (zh) * | 2020-10-29 | 2021-11-19 | 北京莱瑞森医药科技有限公司 | 一种米拉贝隆缓释组合物及其制备方法和应用 |
| JP2023066053A (ja) * | 2021-10-28 | 2023-05-15 | 東和薬品株式会社 | 放出制御医薬組成物 |
| CN114306262B (zh) * | 2021-12-30 | 2023-09-05 | 乐泰药业有限公司 | 米拉贝隆缓释片及其制备方法和质量检测方法 |
| EP4338729A1 (en) * | 2022-09-19 | 2024-03-20 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A tablet comprising mirabegron |
| JP2025115978A (ja) * | 2024-01-26 | 2025-08-07 | 富士化学工業株式会社 | 徐放性製剤 |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| JPH03145418A (ja) | 1989-10-27 | 1991-06-20 | Sumitomo Pharmaceut Co Ltd | 塩基性薬物塩酸塩の徐放性製剤 |
| GB9111426D0 (en) | 1991-05-28 | 1991-07-17 | Ici Plc | Chemical compounds |
| DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
| CA2144077C (en) * | 1992-09-18 | 2005-05-24 | Kazuhiro Sako | Hydrogel-type sustained-release preparation |
| DK0707475T3 (da) | 1993-06-14 | 1997-12-29 | Janssen Pharmaceutica Nv | Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| NZ283160A (en) | 1994-05-06 | 1998-07-28 | Pfizer | Azithromycin in a controlled release dosage form for treating microbiol infections |
| GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
| EP2065055A1 (en) | 1996-06-26 | 2009-06-03 | Board of Regents, The University of Texas System | Holt-melt extrudable pharmaceutical formulation |
| WO1998000016A1 (en) | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| JP4685201B2 (ja) | 1996-08-19 | 2011-05-18 | キッセイ薬品工業株式会社 | 頻尿および尿失禁の予防・治療剤 |
| EP1014957A4 (en) | 1997-08-28 | 2004-01-28 | Afferon Corp | URINARY INCONTINENCE THERAPY |
| DK1028111T3 (da) | 1997-10-17 | 2004-09-20 | Yamanouchi Pharma Co Ltd | Amidderivater eller salte heraf |
| WO1999031045A1 (en) | 1997-12-18 | 1999-06-24 | Kissei Pharmaceutical Co., Ltd. | Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| NZ507486A (en) | 1998-04-14 | 2003-03-28 | Kissei Pharmaceutical | 2-methylpropionic acid derivatives and pharmaceutical uses thereof |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| MY126489A (en) | 1998-07-08 | 2006-10-31 | Kissei Pharmaceutical | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
| DE19842753A1 (de) | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
| US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
| PT1205190E (pt) | 1999-08-04 | 2006-09-29 | Astellas Pharma Inc | Composicoes medicinais estaveis para uso oral utilizando oxidos de ferro |
| GB2356197A (en) | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| JP2001114736A (ja) | 1999-10-19 | 2001-04-24 | Kissei Pharmaceut Co Ltd | ２−アミノプロパノール誘導体 |
| US8012504B2 (en) | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US6419954B1 (en) | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| US6368628B1 (en) | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| EP1326861A1 (en) | 2000-10-20 | 2003-07-16 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| GB0117618D0 (en) | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
| US20030072802A1 (en) | 2001-10-11 | 2003-04-17 | R.T. Alamo Ventures, Inc. | Sustained release topiramate |
| US7342117B2 (en) | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| IL161491A0 (en) | 2001-11-07 | 2004-09-27 | Synthon Bv | Tamsulosin tablets |
| CA2471096A1 (en) * | 2001-12-19 | 2003-07-03 | Alza Corporation | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| DE60323964D1 (de) | 2002-04-29 | 2008-11-20 | Alza Corp | Poly(alkylenoxide) von reduziertem format mit reboxetin zur verringerung der bildung von verunreinigungen |
| GEP20094759B (en) | 2002-10-24 | 2009-08-25 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| AU2003284700B2 (en) | 2002-11-07 | 2009-05-28 | Astellas Pharma Inc. | Remedy for overactive bladder comprising acetic acid anlide derivatives as the active ingredient |
| EP1424079A1 (en) | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| US7442387B2 (en) * | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| DK1492519T3 (da) | 2003-03-21 | 2007-03-05 | Dynogen Pharmaceuticals Inc | Fremgangsmåder til behandling af lidelser i den nedre urinvej ved anvendelse af alfa-2-delta-underenhedscalciumkanalsmodulatorer med glat muskel-modulatorer |
| EP1631251B1 (en) | 2003-04-24 | 2011-06-15 | Jagotec AG | Delayed release tablet with defined core geometry |
| US20050042289A1 (en) | 2003-04-29 | 2005-02-24 | Yamanouchi Pharma Technologies, Inc. | Tablets and methods for modified release of hydrophylic and other active agents |
| EP1663217B1 (en) | 2003-08-29 | 2010-07-07 | LifeCycle Pharma A/S | Solid dispersions comprising tacrolimus |
| DE602004030931D1 (enExample) | 2003-11-04 | 2011-02-17 | Supernus Pharmaceuticals Inc | |
| DE10352132A1 (de) | 2003-11-04 | 2005-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten |
| US8197846B2 (en) | 2003-11-10 | 2012-06-12 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
| US8128958B2 (en) | 2003-11-10 | 2012-03-06 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
| JP2005162737A (ja) * | 2003-11-10 | 2005-06-23 | Astellas Pharma Inc | 徐放性医薬組成物 |
| JP2005162736A (ja) | 2003-11-10 | 2005-06-23 | Astellas Pharma Inc | 徐放性医薬組成物 |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| EP2283825B1 (en) | 2004-05-24 | 2022-04-13 | Allergan Pharmaceuticals International Limited | Enteric solid oral dosage form of a bisphosphonate containing a chelating agent |
| WO2006009769A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
| US20050287185A1 (en) | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
| CN101068546A (zh) | 2004-10-06 | 2007-11-07 | 卫材R&D管理有限公司 | 医药组合物及其制造方法以及医药组合物中的二氢吡啶类化合物的稳定化方法 |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| JP2008532953A (ja) | 2005-03-08 | 2008-08-21 | ライフサイクル ファーマ エー／エス | シロリムスおよび／またはその類縁物質を含む医薬組成物 |
| EP1769792A1 (de) | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
| WO2007080776A1 (ja) | 2006-01-10 | 2007-07-19 | Kissei Pharmaceutical Co., Ltd. | 徐放性製剤およびその製造方法 |
| JPWO2008084698A1 (ja) | 2006-12-28 | 2010-04-30 | アステラス製薬株式会社 | タクロリムス徐放性医薬組成物 |
| EP2175843B1 (en) | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| WO2009052353A2 (en) | 2007-10-17 | 2009-04-23 | Dr. Reddy's Laboratories Ltd. | Trospium pharmaceutical formulations |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| US20120070465A1 (en) | 2010-03-29 | 2012-03-22 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
| US8877214B2 (en) | 2010-03-29 | 2014-11-04 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
| US8898159B2 (en) | 2010-09-28 | 2014-11-25 | International Business Machines Corporation | Providing answers to questions using logical synthesis of candidate answers |
-
2009
- 2009-09-25 TW TW098132502A patent/TWI478712B/zh active
- 2009-09-28 DK DK09817723.1T patent/DK2345410T3/da active
- 2009-09-28 LT LTEP09817723.1T patent/LT2345410T/lt unknown
- 2009-09-28 CA CA2740342A patent/CA2740342C/en active Active
- 2009-09-28 MX MX2011003445A patent/MX351855B/es active IP Right Grant
- 2009-09-28 CN CN201510642287.2A patent/CN105232448A/zh active Pending
- 2009-09-28 SI SI200932110T patent/SI2345410T1/sl unknown
- 2009-09-28 RU RU2011117274/15A patent/RU2495666C2/ru active
- 2009-09-28 HR HRP20210179TT patent/HRP20210179T1/hr unknown
- 2009-09-28 ES ES09817723T patent/ES2847876T3/es active Active
- 2009-09-28 EP EP20212426.9A patent/EP3827826A1/en active Pending
- 2009-09-28 AU AU2009300752A patent/AU2009300752C1/en active Active
- 2009-09-28 CN CN2009801386919A patent/CN102170878A/zh active Pending
- 2009-09-28 PT PT98177231T patent/PT2345410T/pt unknown
- 2009-09-28 JP JP2010531838A patent/JP4688089B2/ja active Active
- 2009-09-28 US US12/568,313 patent/US20160184275A2/en not_active Abandoned
- 2009-09-28 KR KR1020117009897A patent/KR101524164B1/ko active Active
- 2009-09-28 BR BRPI0919466-5A patent/BRPI0919466B1/pt not_active IP Right Cessation
- 2009-09-28 WO PCT/JP2009/066742 patent/WO2010038690A1/ja not_active Ceased
- 2009-09-28 PL PL09817723T patent/PL2345410T3/pl unknown
- 2009-09-28 HU HUE09817723A patent/HUE052874T2/hu unknown
- 2009-09-28 EP EP09817723.1A patent/EP2345410B1/en active Active
-
2010
- 2010-12-13 JP JP2010276634A patent/JP5625855B2/ja active Active
-
2011
- 2011-03-30 IL IL212033A patent/IL212033A/en active IP Right Grant
- 2011-03-31 ZA ZA2011/02406A patent/ZA201102406B/en unknown
-
2016
- 2016-04-13 HK HK16104217.1A patent/HK1216232A1/zh unknown
-
2017
- 2017-02-14 US US15/432,854 patent/US10842780B2/en active Active
-
2020
- 2020-11-19 US US16/952,795 patent/US20210322387A1/en not_active Abandoned
-
2021
- 2021-01-18 CY CY20211100034T patent/CY1123724T1/el unknown
-
2024
- 2024-03-22 US US18/613,270 patent/US12059409B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011079859A5 (enExample) | ||
| EP3417861B1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
| US20250144112A1 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
| RU2011117274A (ru) | Фармацевтическая композиция для модифицированного высвобождения | |
| AU2011273519B2 (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl]-1H-quinolin-2-one lactate monohydrate | |
| US12016951B2 (en) | Edaravone pharmaceutical composition | |
| AU2012340759C1 (en) | Pharmaceutical formulations | |
| JP2015501808A5 (enExample) | ||
| BR112020018697A2 (pt) | Composição farmacêutica incluindo alquilsulfato de sódio | |
| KR101923403B1 (ko) | 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물 | |
| ES2934702T3 (es) | Comprimido que contiene mirabegrón, método para producir una preparación farmacéutica que contiene mirabegrón y método para producir un producto granulado que contiene mirabegrón | |
| CN107530342A (zh) | 口服给药用医药组合物 | |
| JPWO2009123169A1 (ja) | アミド誘導体含有医薬組成物 | |
| KR101721831B1 (ko) | 로베글리타존을 함유하는 경구 투여용 약제학적 조성물 | |
| EP2839829A1 (en) | Sustained release tablet containing levodropropizine and method for preparing same | |
| JP6123795B2 (ja) | 放出制御医薬組成物 | |
| EP2925320B1 (en) | Novel method for improving the bioavailability of low aqueous solubility drugs | |
| WO2015003109A1 (en) | Capsule formulation comprising fexofenadine | |
| JP2016222651A (ja) | ミグリトール含有口腔内崩壊錠 | |
| US10391178B2 (en) | Premix of crystalline raltegravir potassium salt and a process for the preparation thereof | |
| WO2011086577A2 (en) | Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts | |
| KR101461271B1 (ko) | 시베레스타트 나트륨염 또는 그 수화물을 함유하는 주사용 제제 | |
| JP6150564B2 (ja) | 口腔内速崩壊性錠剤 | |
| WO2014027973A1 (en) | Paliperidone oral solution | |
| IL261179A (en) | Pemetrexed formulations |